Biogen Inc. (BIIB) News
Follow Biogen Inc. (BIIB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 71 public stories across 28 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Argus Research Upgrades Biogen to Buy, Sets $280 Price Target
Argus Research upgraded Biogen to Buy from Hold and set a $280 price target. The target implies 12.2% upside from the Oct. 29 close of $249.65.
EQUITY | Oct 29, 2026, 09:34 PM UTC
M
Idorsia 9M Revenue Flat; QUVIVIQ Sales Rise 54%
Swiss biopharma company Idorsia reported flat revenue for the first nine months of 2026, while QUVIVIQ sales increased 54%.
EARNINGS | Oct 29, 2026, 06:17 AM UTC
M
BIIB Reports Fiscal Q3 Profit, Down 70.46%
Basic earnings per share were reported.
EQUITY | Oct 29, 2026, 03:10 AM UTC
M
BioInvent Q3 Sales Rise as Loss Narrows
BioInvent reported higher net sales and a narrower loss in the third quarter.
EQUITY | Oct 28, 2026, 11:28 PM UTC
M
Biogen Beats Quarterly Estimates on Rare Disease Drug Success
Biogen exceeded quarterly estimates, attributed in the headline to the success of its rare disease drugs.
EARNINGS | Oct 28, 2026, 02:32 PM UTC
M
Biogen übertrifft Quartalsprognosen dank starker Nachfrage nach Medikamenten gegen seltene Krankheiten
EARNINGS | Oct 28, 2026, 02:32 PM UTC
M
Biogen Raises 2026 Adjusted EPS Floor by 20 Cents
Biogen raised the lower end of its 2026 adjusted EPS guidance by 20 cents. Rare-disease revenue increased 27%.
EARNINGS | Oct 28, 2026, 02:32 PM UTC
M
Biogen Beats Quarterly Forecasts on Rare-Disease Drug Success
EARNINGS | Oct 28, 2026, 02:31 PM UTC
M
Biogen Beats Quarterly Estimates on Rare-Disease Drug Performance
EARNINGS | Oct 28, 2026, 02:31 PM UTC
M
Biogen tops quarterly estimates on rare-disease drug strength
EARNINGS | Oct 28, 2026, 02:30 PM UTC
M
Biogen Executive Expects Growth From Apellis Acquisition
A Biogen executive expects the Apellis acquisition to drive growth even without its pipeline, according to a conference call.
MNA | Oct 28, 2026, 12:55 PM UTC
M
Biogen Reports Q3 2026 Results, Raises EPS Guidance
Biogen reported adjusted Q3 2026 EPS of $2.62 and revenue of $2.80 billion, above FactSet consensus estimates of $1.99 and $2.63 billion, respectively. It raised the low end of its fiscal 2026 non-GAAP EPS guidance to $1
EQUITY | Oct 28, 2026, 11:32 AM UTC
M
Biogen Swings to Quarterly Loss as Sales Rise
Biogen reported a third-quarter loss of $20.6 million, or 14 cents a share, compared with a year-earlier profit of $466.5 million, or $3.17 a share. Sales increased.
EQUITY | Oct 28, 2026, 10:43 AM UTC
M
Biogen Reports Third-Quarter Revenue of $2.8 Billion
EQUITY | Oct 28, 2026, 10:31 AM UTC
M
Biogen Q3 Revenue Beats on Apellis Acquisition and Product Demand
EQUITY | Oct 28, 2026, 10:17 AM UTC
M
Biogen Sees 2026 Revenue Up Mid-Single Digits
EARNINGS | Oct 28, 2026, 10:15 AM UTC
M
Biogen Sees 2026 Adjusted EPS of $12.20–$13.00
EARNINGS | Oct 28, 2026, 10:14 AM UTC
M
Biogen Swings to Q3 2026 Net Loss of $20.6 Million
Biogen reported a GAAP net loss of $20.6 million for the third quarter of 2026.
EQUITY | Oct 28, 2026, 10:13 AM UTC
L
Biogen Reports Third-Quarter Free Cash Flow of About $600 Million
EQUITY | Oct 28, 2026, 10:13 AM UTC
M
Biogen reports Q3 Leqembi in-market revenue of $202 million
EQUITY | Oct 28, 2026, 10:12 AM UTC
L
Biogen Reports Q3 EPS of USD -0.14
EARNINGS | Oct 28, 2026, 10:11 AM UTC
M
Biogen Q3 Adjusted EPS $2.62 vs IBES Estimate $1.99
EARNINGS | Oct 28, 2026, 10:09 AM UTC
M
Biogen reports third-quarter loss per share
EQUITY | Oct 28, 2026, 10:08 AM UTC
M
Biogen Q3 Revenue $2.80 Billion vs. IBES Estimate $2.63 Billion
EQUITY | Oct 28, 2026, 10:05 AM UTC
L
Biogen beats third-quarter results on rare-disease drug strength
EARNINGS | Oct 28, 2026, 10:04 AM UTC
M
Biogen Q3 Earnings Preview: Analysts Estimate EPS
Biogen is scheduled to report Q3'26 results on October 28 before the market opens. Revenue and EPS estimates are available ahead of the report.
EQUITY | Oct 27, 2026, 11:01 AM UTC
H
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of pharmaceutical companies Kodiak Sciences Inc. (KOD), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.KOD stock surged
EARNINGS | Sep 29, 2026, 04:24 AM UTC
L
AI-based drug developer Basecamp valued at $800 million after $140 million funding round
By Puyaan SinghBasecamp Research said on Wednesday it has raised $140 million in a Series C funding round that valued the AI-based drug developer at $800 million.The oversubscribed round was led by S32, with participatio
NEWS | Sep 23, 2026, 01:00 PM UTC
M
LEQEMBI Pen approved in Japan for early Alzheimer’s
Eisai and Biogen said Japan approved LEQEMBI Pen, the subcutaneous formulation of lecanemab, for early Alzheimer’s disease treatment.
REGULATION | Sep 18, 2026, 03:44 PM UTC
M
Eisai and Biogen announce Japan approval of LEQEMBI Pen
Eisai and Biogen said Japan approved “LEQEMBI Pen,” a subcutaneous formulation for early Alzheimer’s disease.
REGULATION | Sep 16, 2026, 06:01 AM UTC
L
Biogen price target raised to $175 from $165 by HSBC
HSBC raised its Biogen price target to $175.00 per share from $165.00, according to Ratings actions reported by Benzinga (TradingView News).
EQUITY | Sep 10, 2026, 02:19 PM UTC
L
BIIB: Diversification, disciplined investment, and pipeline execution drive growth and resilience
Management highlighted strategic diversification beyond neurology, disciplined capital allocation, and operational efficiency. Key growth drivers include a robust late-stage pipeline, expansion into nephrology and immuno
EQUITY | Sep 09, 2026, 02:52 PM UTC
L
BIIB: pipeline progress and disciplined capital allocation highlighted
BIIB management cited diversification beyond neurology and pipeline momentum, including ten phase III programs, alongside disciplined capital allocation. New launches and acquisitions are set to offset legacy declines, w
EQUITY | Sep 09, 2026, 02:36 PM UTC
M
China NMPA approves subcutaneous lecanemab for early Alzheimer’s
Eisai and Biogen said China’s NMPA approved a lecanemab subcutaneous formulation for initiation treatment in early Alzheimer’s, using a subcutaneous autoinjector (SC-AI).
GEOPOLITICS | Sep 08, 2026, 07:47 PM UTC
M
Canada drug agency gives final positive reimbursement recommendation for lecanemab
Eisai and Biogen said Canada’s Drug Agency (CDA-AMC) issued a final recommendation supporting public reimbursement of LEQEMBI (lecanemab) for eligible early Alzheimer’s disease patients in Canada.
EQUITY | Sep 08, 2026, 03:10 PM UTC
L
Stoke and Biogen present long-term Zorevunersen data at EEC
Stoke Therapeutics and Biogen announced presentations of long-term clinical data supporting the disease-modifying potential of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy
GEOPOLITICS | Sep 03, 2026, 11:30 PM UTC
L
Biogen price target raised to $245 from $225 by Piper Sandler
Piper Sandler raised its price target on Biogen to $245.00 per share from $225.00, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 05:42 PM UTC
L
Stoke and Biogen to present Zorevunersen clinical data at EEC
Stoke Therapeutics and Biogen announced presentations of clinical data from studies of Zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress (EEC) in September.
GEOPOLITICS | Sep 01, 2026, 11:30 AM UTC
L
Leqembi Iqlik autoinjector available in U.S. for early Alzheimer’s
Leqembi Iqlik autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer’s disease.
EQUITY | Aug 27, 2026, 06:58 PM UTC
L
Biogen’s Leqembi iqlik autoinjector available in U.S. for early Alzheimer’s
Eisai and Biogen said the Leqembi iqlik (lecanemab-irmb) autoinjector is now available in the U.S. to initiate therapy for early Alzheimer’s disease.
EQUITY | Aug 24, 2026, 12:02 PM UTC
M
Biogen's Leqembi Iqlik autoinjector now available in U.S.
Biogen says the LEQEMBI IQLIK autoinjector for initiation of therapy is now available in the U.S. for early Alzheimer’s disease.
REGULATION | Aug 24, 2026, 12:01 PM UTC
H
Biogen Acquires RayThera Inc
Biogen completes acquisition of RayThera
MNA | Aug 06, 2026, 10:15 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
H
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen Inc. (NASDAQ: BIIB ) stock is trading higher on Wednesday after the company reported second-quarter adjusted earnings of $3.60 per share, beating the consensus of $2.96. Revenue Tops Expectations On Growth Across
EARNINGS | Jul 29, 2026, 05:36 PM UTC
H
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guida
Biogen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 adjusted EPS guidance above estimates. Also, Barclays raised its price target on the stock from $1
EARNINGS | Jul 29, 2026, 03:27 PM UTC
H
CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est
Biogen (NASDAQ: BIIB ) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 analyst estimate..
EARNINGS | Jul 29, 2026, 01:12 PM UTC
M
Biogen to be less intentional about M&A
Biogen adopts opportunistic M&A approach
MNA | Jul 29, 2026, 12:42 PM UTC
L
BIIB Biogen - middle East conflict did not have any material effects on our results of operations for three and six months ended June 30, 20
BIIB Biogen - middle East conflict did not have any material effects on our results of operations for three and six months ended June 30, 2026
EQUITY | Jul 29, 2026, 10:43 AM UTC
M
BIIB: No Refund Recorded for IEEPA Tariffs
BIIB doesn't record tariff refund receivable
EQUITY | Jul 29, 2026, 10:41 AM UTC
M
Biogen: Tariffs Won't Hurt 2026 Operations
Biogen expects no material impact from tariffs
EQUITY | Jul 29, 2026, 10:40 AM UTC
H
BIIB Q2 EPS $3.60 vs. est. $2.95; Q2 revs $2.736B vs. est. $2.46B; lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25 (est. $12.72); F
BIIB Q2 EPS $3.60 vs. est. $2.95; Q2 revs $2.736B vs. est. $2.46B; lowers FY26 EPS view to $12.00-$13.00 from $14.25-$15.25 (est. $12.72); FY revs now expected to increase by a mid-single digit percentage for 2026 as com
EARNINGS | Jul 29, 2026, 10:19 AM UTC
H
Biogen Lowers FY2026 Adj EPS Guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 Est
Biogen (NASDAQ: BIIB ) lowers FY2026 Adj EPS guidance from $14.25-$15.25 to $12.00-$13.00 vs $12.83 analyst estimate..
EARNINGS | Jul 29, 2026, 10:16 AM UTC
H
Biogen 2Q Rev $2.74B, Est. $2.47B
Biogen beats revenue estimates
EARNINGS | Jul 29, 2026, 10:06 AM UTC
H
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.8%, GD +/-3.7%, TEVA +/-6.5%, JCI +/-7.8%, CTSH +/-11.7%, ODFL +/-8.3%, ETR +/-4
EARNINGS | Jul 28, 2026, 06:05 PM UTC
H
BIIB Earnings pre-market tomorrow: qtr EPS est $2.99 (high $3.80/low $1.67), 30-day avg EPS revision -7.3% (3 analyst(s) revised up, 18 down
BIIB Earnings pre-market tomorrow: qtr EPS est $2.99 (high $3.80/low $1.67), 30-day avg EPS revision -7.3% (3 analyst(s) revised up, 18 down), qtr revs est $2.45B; FY EPS est $12.91, FY revs est $10.03B; short interest 4
EARNINGS | Jul 28, 2026, 04:12 PM UTC
L
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
DNLI Unwarranted Selloff in Sympathy to BIIB's Tau ASO for Alzheimer's; raise PT to $35 from $31 @ DBAB
EQUITY | Jul 16, 2026, 12:10 PM UTC
H
Midday Fly By: IBM warns on Q2 outlook, Goldman reports sharp beat
Stocks moved higher after softer inflation data shut the door on a Fed rate hike this month. Both headline and core inflation rates declined, easing the impact of another rally in energy prices after the U.S. and Iran ma
CENTRAL_BANK | Jul 14, 2026, 04:00 PM UTC
L
BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher
BIIB -7% after saying its experimental Alzheimer's drug diranersen missed the main goal of its mid-stage study, which tested whether higher doses provided greater benefit in patients with early Alzheimer's Disease; said
EQUITY | Jul 14, 2026, 01:44 PM UTC
L
BIIB -6.2% after Co's experimental Alzheimer's drug misses main goal in mid-stage study
BIIB -6.2% after Co's experimental Alzheimer's drug misses main goal in mid-stage study
EQUITY | Jul 14, 2026, 01:39 PM UTC
L
BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early
BIIB Biogen presents phase 2 celia data at aaic demonstrating meaningful clinical outcomes and robust Tau reduction with diranersen in early alzheimer’s disease Biogen - to advance diranersen into confirmatory phase 3 de
EQUITY | Jul 14, 2026, 01:15 PM UTC